Haase, Christa http://orcid.org/0000-0003-3273-7982
Gustafsson, Karin
Mei, Shenglin http://orcid.org/0000-0001-8258-5898
Yeh, Shu-Chi http://orcid.org/0000-0003-1898-9665
Richter, Dmitry
Milosevic, Jelena
Turcotte, Raphaƫl
Kharchenko, Peter V.
Sykes, David B. http://orcid.org/0000-0002-9788-0221
Scadden, David T.
Lin, Charles P.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK115577)
U.S. Department of Health & Human Services | National Institutes of Health (R01 CA194596, P01 HL142494)
Article History
Received: 23 December 2021
Accepted: 3 October 2022
First Online: 24 November 2022
Competing interests
: C.H., D.R. and C.P.L. are inventors on a coversheet provisional filed by Massachusetts General Hospital (App. No. 63/394,274, patent application pending) that describes the Image-seq technology. D.B.S. is a founder, consultant and shareholder for Clear Creek Bio. D.T.S. is a director and shareholder for Agios Therapeutics and Editas Medicines; a founder, director, shareholder and scientific advisory board member for Magenta Therapeutics and LifeVault Bio; a shareholder and founder of Fate Therapeutics and Garuda Therapeutics and a director, founder and shareholder for Clear Creek Bio; a consultant for FOG Pharma, Inzen Therapeutics and VCanBio; and a recipient of sponsored research funding from Sumitomo Dianippon. P.V.K. serves on the Scientific Advisory Board to Celsius Therapeutics Inc. and Biomage Inc. All other authors have no competing interests.